scholarly journals Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours

2006 ◽  
Vol 96 (1) ◽  
pp. 49-55 ◽  
Author(s):  
F Marrache ◽  
M P Vullierme ◽  
C Roy ◽  
Y El Assoued ◽  
A Couvelard ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Liver Metastases ◽  
Body Mass ◽  
Arterial Phase ◽  
Endocrine Tumours ◽  
Predictors Of Response

Outcome After Resection of Colorectal Liver Metastases: No Prognostic Influence of Complications, Blood Transfusions or Body Mass Index

2011 ◽  
Vol 140 (5) ◽  
pp. S-1052
Author(s):  
Frank Makowiec ◽  
Hannes P. Neeff ◽  
Andrea Klock ◽  
Oliver Drognitz ◽  
Ulrich T. Hopt
Keyword(s):  
Body Mass Index ◽  
Liver Metastases ◽  
Body Mass ◽  
Colorectal Liver Metastases ◽  
Blood Transfusions

Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive N-acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial

2019 ◽  
Vol 54 (2) ◽  
pp. 159-172 ◽  
Author(s):  
Melanie M Ashton ◽  
Olivia M Dean ◽  
Wolfgang Marx ◽  
Mohammadreza Mohebbi ◽  
Michael Berk ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Diet Quality ◽  
Combination Treatment ◽  
Bipolar Depression ◽  
Controlled Trial ◽  
Depression Symptoms ◽  
Dietary Inflammatory Index ◽  
Inflammatory Index ◽  
Predictors Of Response

Aims: We aimed to explore the relationships between diet quality, dietary inflammatory potential or body mass index and outcomes of a clinical trial of nutraceutical treatment for bipolar depression. Methods: This is a sub-study of a randomised controlled trial of participants with bipolar depression who provided dietary intake data ( n = 133). Participants received 16 weeks adjunctive treatment of either placebo or N-acetylcysteine-alone or a combination of mitochondrial-enhancing nutraceuticals including N-acetylcysteine (combination treatment). Participants were followed up 4 weeks post-treatment discontinuation (Week 20). Diet was assessed by the Cancer Council Victoria Dietary Questionnaire for Epidemiological Studies, Version 2, converted into an Australian Recommended Food Score to measure diet quality, and energy-adjusted dietary inflammatory index score to measure inflammatory potential of diet. Body mass index was also measured. Generalised estimating equation models were used to assess whether diet quality, energy-adjusted dietary inflammatory index score and/or body mass index were predictors of response to significant outcomes of the primary trial: depression symptoms, clinician-rated improvement and functioning measures. Results: In participants taking combination treatment compared to placebo, change in depression scores was not predicted by Australian Recommended Food Score, dietary inflammatory index or body mass index scores. However, participants with better diet quality (Australian Recommended Food Score) reported reduced general depression and bipolar depression symptoms ( p = 0.01 and p = 0.03, respectively) and greater clinician-rated improvement ( p = 0.02) irrespective of treatment and time. Participants who had a more anti-inflammatory dietary inflammatory index had less impairment in functioning ( p = 0.01). Combination treatment may attenuate the adverse effects of pro-inflammatory diet ( p = 0.03) on functioning. Participants with lower body mass index who received combination treatment ( p = 0.02) or N-acetylcysteine ( p = 0.02) showed greater clinician-rated improvement. Conclusion: These data support a possible association between diet (quality and inflammatory potential), body mass index and response to treatment for bipolar depression in the context of a nutraceutical trial. The results should be interpreted cautiously because of limitations, including numerous null findings, modest sample size and being secondary analyses.

191: Does the Body Mass Index Affect the Outcome Following Reconstruction of Orthotopic Neobladder?

2007 ◽  
Vol 177 (4S) ◽  
pp. 64-64
Author(s):  
Murugesan Manoharan ◽  
Martha A. Reyes ◽  
Alan M. Nieder ◽  
Bruce R. Kava ◽  
MarkS Soloway
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
The Body ◽  
Orthotopic Neobladder

477: Body Mass Index and Impact on PSA Screening and Prostate Cancer Detection in the Plco Trial

2006 ◽  
Vol 175 (4S) ◽  
pp. 155-155
Author(s):  
Robert L. Grubb ◽  
David L. Levin ◽  
Paul F. Pinsky ◽  
Jerome Mabie ◽  
Thomas L. Riley ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Cancer Detection ◽  
Prostate Cancer Detection ◽  
Psa Screening

1887: Predicting ESWL Stone-Free Rates Using Body Mass Index and Hounsfield Units

2004 ◽  
Vol 171 (4S) ◽  
pp. 498-499
Author(s):  
Gyan Pareek ◽  
J. James Bruno ◽  
Georgia Panagopoulos ◽  
Noel A. Armenakas ◽  
John A. Fracchia
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Hounsfield Units

1480: The Association of Body Mass Index and Serum Prostate Specific Antigen Levels in a Population-Based Study

2005 ◽  
Vol 173 (4S) ◽  
pp. 401-401
Author(s):  
Javier Hernandez ◽  
Jacques Baillargeon ◽  
Brad Pollock ◽  
Alan R. Kristal ◽  
Patrick Bradshaw ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Prostate Specific Antigen ◽  
Body Mass ◽  
Specific Antigen ◽  
Population Based ◽  
Population Based Study ◽  
Serum Prostate Specific Antigen
Sign in / Sign up

Export Citation Format

Share Document